Harnessing the power of the endocannabinoid system.

Our goal is to become a global leader in the development of safe and effective prescription medicines to treat serious and life-threatening human diseases and conditions. OCT's primary focus is on the development for indications in severe, chronic pain conditions, that remain one of the biggest challenges facing society today.

 

Find out more

Our Approach

OCT utilises a range of compounds in drug development, including proprietary cannabinoid derivatives, natural phytocannabinoids and completely new chemical entities (NCEs) that target the endocannabinoid system. By utilising a range of inputs, OCT is creating a drug development portfolio that maximises the therapeutic potential of cannabinoids, long-term market value, and market exclusivity across all activities.

 

Find out more

Meet the Team

With experience across pharmaceutical operations, R&D, intellectual property, law and finance, OCT's team is committed to excellence. Together, we are passionate about delivering breakthrough therapies for life-threatening conditions with a significant unmet medical need.

 

Find out more

Recent news, reports & resources

 

All News

  • Oxford Cannabinoid Technologies "ready to go" after phase 1 trial submission

    06 January 2023 Proactive Interview
  • Oxford Cannabinoid Technologies hails 'milestone' as it submits Phase I trial application for lead programme

    05 January 2023 OCT Milestone
  • Oxford Cannabinoid Technologies nearly ready for new Phase 1 trial

    14 November 2022 Proactive Interview

Get in touch

Oxford Cannabinoid Technologies Ltd

Prama House
267 Banbury Road
Oxford
OX2 7HT

Find us on a map